摘要
目的：比较力确兴与复达欣治疗绿脓杆菌下呼吸道感染的安全有效性。方法：采用随机对照试验设计，全部病例均为住院患者，试验组２０例，力确兴注射液，每次２００ｍｇ每日２次（每２小时１次），溶于１００～２００ｍｌ０９％氯化钠溶液或５％葡萄糖溶液中稀释，滴注时间１小时半至２小时。对照组１９例，复达欣２ｇ溶于５％葡萄糖溶液２００ｍｌ中静脉滴注，每日２次。试验组和对照组疗程均为７～１４天。一般资料相似（Ｐ＞００５）。结果：试验组与对照组临床疗效比较治疗前后发热病人体温转为正常的天数、白细胞增加的病人７天后白细胞转为正常的例数均无显著性差异（Ｐ＞００５）。治疗结束后，试验组２０例中１３例治愈；对照组１９例中１４例治愈，两组的治愈率分别为６５％和７３７％（Ｐ＝０９００）。试验组和对照组显效、进步、无效分别为２例和１例、２例和２例、３例和２例，两组均无显著性差异（Ｐ＝０７５０～０９００）。有效例数分别为１７例（８５％）和１７例（８９５％），以对照组为高，但无统计学差异（Ｐ＝０９５０）。药物敏试结果发现３７株绿脓杆菌对力确兴敏感（包括高敏和中敏），３６株对复达欣敏感；２株对力确兴耐药，３株对复达欣耐药。经统计学处?
Objective:The study was to evaluate and compare the efficacy and safety of
ceftazidime and netilmicin in treating pseudomonas aeruginosa infection of low respiratory
tract.Method:In this randomized and comparative study,patients received 200mg netilmicin
intravenously twice a day (trial group),or 2g ceftazidime intravenously twice a day(control
group).39 patients were enrolled in the study.The course of treatment was 714 days.Result:The
efficacy of ceftazidime and netilmicin were 895%,85% respectively(P=0950).By determining the
drug susceptibility of pseudomonas aeruginosa to the antibiotics,it was found that the
susceptive stains to ceftazidime and netilmicin were 36,37 respectively,and the resistive stains
were 3,2 respectivAuthor ely.(P=0750).The adverse drug reaction were light.Conclusion:Data
obtained in our study indicate that for the majority of patients with pseudomonas aeruginosa
low respiratory tract infection,netilmicin and ceftazidime are effective and safe,and the adverse
reaction rates are low.
出处
《华西医学》
CAS
1999年第2期140-142,共3页
West China Medical Journal
